Cargando…
Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678394/ https://www.ncbi.nlm.nih.gov/pubmed/33214229 http://dx.doi.org/10.1136/esmoopen-2020-001112 |
| _version_ | 1783612146501812224 |
|---|---|
| author | Franzoi, Maria Alice de Azambuja, Evandro |
| author_facet | Franzoi, Maria Alice de Azambuja, Evandro |
| author_sort | Franzoi, Maria Alice |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7678394 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76783942020-11-30 Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? Franzoi, Maria Alice de Azambuja, Evandro ESMO Open Editorial BMJ Publishing Group 2020-11-19 /pmc/articles/PMC7678394/ /pubmed/33214229 http://dx.doi.org/10.1136/esmoopen-2020-001112 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Editorial Franzoi, Maria Alice de Azambuja, Evandro Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title_full | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title_fullStr | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title_full_unstemmed | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title_short | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| title_sort | atezolizumab in metastatic triple-negative breast cancer: impassion130 and 131 trials - how to explain different results? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678394/ https://www.ncbi.nlm.nih.gov/pubmed/33214229 http://dx.doi.org/10.1136/esmoopen-2020-001112 |
| work_keys_str_mv | AT franzoimariaalice atezolizumabinmetastatictriplenegativebreastcancerimpassion130and131trialshowtoexplaindifferentresults AT deazambujaevandro atezolizumabinmetastatictriplenegativebreastcancerimpassion130and131trialshowtoexplaindifferentresults |